Backblaze to Showcase AI-Powered Media Archive Solutions in Partnership Webinar with TwelveLabs
Companies to demonstrate how cloud storage and multimodal AI unlock new monetization opportunities for media organizations
Article content
SAN MATEO, Calif. — Backblaze, Inc. (Nasdaq: BLZE), the cloud storage innovator providing a modern alternative to traditional cloud providers, today announced it will participate in a joint webinar with TwelveLabs titled ' Unlock Your Media Archive: Faster Access and New Monetization Opportunities with Cloud Storage and AI.'
Article content
The August 14 webinar begins at 10:00 a.m. PT and will demonstrate how media organizations can transform their archived video content into searchable, monetizable assets by combining Backblaze B2 Cloud Storage with TwelveLabs' advanced multimodal AI video understanding platform.
Article content
TwelveLabs, a leading AI company specializing in video understanding technology, has built foundation models that can analyze visual, audio, and text content within videos, enabling deep semantic search across media archives. Their partnership with Backblaze allows organizations to store vast video libraries cost-effectively while making them instantly searchable and actionable through AI-powered insights.
Article content
During the live session, attendees will learn how the integrated solution enables media companies to rescue their high-value content from tape shelves and legacy silos and fuel new revenue opportunities. The panel will share real-world success stories and provide a practical roadmap for migrating, enriching, and monetizing archives.
Article content
'Media organizations are sitting on goldmines of archived content that's essentially locked away because it's too time-consuming and expensive to catalog and search manually,' said Pat Patterson, Chief Technical Evangelist at Backblaze. 'By combining our cost-effective cloud storage with TwelveLabs' AI video understanding capabilities, we're helping companies unlock the true value of their media archives and create new revenue streams from content they already own.'
Article content
About Backblaze
Article content
Backblaze is the cloud storage innovator delivering a modern alternative to traditional cloud providers. We offer high-performance, secure cloud object storage that customers use to develop applications, manage media, secure backups, build AI workflows, protect from ransomware, and more. Backblaze helps businesses break free from the walled gardens that traditional providers lock customers into, enabling them to use their data in open cloud workflows with the providers they prefer at a fraction of the cost. Headquartered in San Mateo, CA, Backblaze (NASDAQ: BLZE) was founded in 2007 and serves over 500,000 customers in 175 countries around the world. For more information, please go to www.backblaze.com.
Article content
About TwelveLabs
Article content
TwelveLabs delivers industry-leading video AI solutions that unlock the full potential of vast video libraries. Our proprietary multimodal foundation models bring human-like understanding to videos, enabling precise semantic search, summarization, analysis and Q&A through easy-to-integrate APIs. This empowers enterprises to effortlessly search, monetize IP, extract insights, and repurpose content at scale.
Article content
Unlike conventional methods that struggle with video, TwelveLabs overcomes the limitations of manual tagging and inadequate computer vision techniques, streamlining processes with customizable models. These models make previously inaccessible video assets searchable, seamlessly integrating into existing workflows. From industry leaders in media and entertainment to governments around the world, TwelveLabs is changing the way the world works with video.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Press Contact:
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
CareTrust REIT, Inc. Announces Pricing of Upsized Public Offering of Common Stock
CareTrust REIT, Inc. (NYSE: CTRE) ('CareTrust REIT' or the 'Company') announced the pricing of its upsized underwritten public offering of 20,000,000 shares of common stock at a price to the public of $32.00 per share. The offering is expected to close on August 14, 2025, subject to customary closing conditions. In connection with the offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock. The Company intends to contribute the net proceeds to CTR Partnership, L.P., its operating partnership, which will in turn use the proceeds from this offering to fund new investments and repay the borrowings outstanding on its revolving credit facility. J.P. Morgan, BofA Securities and RBC Capital Markets are acting as joint lead book-running managers for the offering. BMO Capital Markets, KeyBanc Capital Markets, Morgan Stanley and Wells Fargo Securities are also acting as joint book-running managers for the offering. Huntington Capital Markets, M&T Securities and Raymond James are acting as co-managers for the offering. A shelf registration statement (including prospectus) relating to the Company's common stock was previously filed with the Securities and Exchange Commission (the 'SEC') and was automatically effective upon filing. This offering may only be made by means of a prospectus supplement and the accompanying prospectus. A copy of the preliminary prospectus supplement relating to this offering was filed with the SEC on August 12, 2025, and a final prospectus supplement relating to the offering will be filed with the SEC. A copy of the final prospectus supplement, when available, and accompanying prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@ and postsalemanualrequests@ BofA Securities, Inc., Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, or by email at or RBC Capital Markets, LLC, 200 Vesey Street, 8th Floor, New York, NY 10281-8098, Attention: Equity Syndicate, by telephone at 877-822-4089, or by email at equityprospectus@ You may also obtain a copy of the preliminary prospectus supplement and accompanying prospectus and, when available, the final prospectus supplement and accompanying prospectus, without charge, by visiting the SEC's website at This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About CareTrust REIT™ CareTrust REIT, Inc. is a self-administered, publicly-traded real estate investment trust engaged in the ownership, acquisition, development and leasing of skilled nursing, seniors housing and other healthcare-related properties. With a portfolio of long-term net-leased properties spanning the United States and United Kingdom, and a growing portfolio of quality operators leasing them, CareTrust is pursuing both external and organic growth opportunities across the US and internationally.
Globe and Mail
an hour ago
- Globe and Mail
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ('Compass') (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Compass are expected to be approximately $120 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about August 14, 2025, subject to customary closing conditions. In addition, Compass has granted the underwriters a 30-day option to purchase up to 6,000,000 additional shares of common stock at the public offering price, less the underwriting discount. Compass intends to use the net proceeds from the offering to conduct initial preparations for commercial readiness, to fund research and clinical development of its product candidates, and for general corporate purposes. Jefferies, Piper Sandler and Guggenheim Securities are acting as joint active bookrunning managers for the offering. Raymond James, Wedbush PacGrow and H.C. Wainwright & Co. are acting as lead managers for the offering. Ladenburg Thalmann and D. Boral Capital are acting as co-managers for the offering. A shelf registration statement on Form S-3 relating to the securities offered in the public offering described above was filed with the Securities and Exchange Commission (the 'SEC') on August 30, 2024 and declared effective by the SEC on September 6, 2024. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at A final prospectus supplement and accompanying prospectus will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@ Piper Sandler & Co. by mail at 350 North 5 th Street, Suite 1000, Minneapolis, Minnesota 55401 or by email at prospectus@ and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8 th Floor, New York, NY 10017, telephone: (212) 518-9544, email: GSEquityProspectusDelivery@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Forward-Looking Statements Various statements in this release concerning the timing and completion of the public offering on the anticipated terms or at all may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of substantial risks and uncertainties, many of which are outside Compass's control, that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in Compass's stock price, changes in market conditions, the final terms of the public offering and satisfaction of customary closing conditions related to the public offering, as well as those risks more fully discussed in the section entitled 'Risk Factors' in the prospectus supplement and registration statement referenced above and in Compass's Annual Report on Form 10-K for the year ended December 31, 2024, filed on February 27, 2025 with the SEC and subsequent reports with the SEC. There can be no assurance that Compass will be able to complete the public offering on the anticipated terms. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Compass undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.
Globe and Mail
3 hours ago
- Globe and Mail
Occidental Petroleum's Resilient Q2 2025 Performance
Occidental Petroleum Corp. ((OXY)) has held its Q2 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Occidental Petroleum Corp.'s recent earnings call painted a picture of resilience and strategic advancement, despite facing challenges from lower oil prices and oversupply issues in its OxyChem segment. The company emphasized its strong operational performance, significant debt reduction, and progress in low carbon ventures, showcasing its preparedness for future growth. Strong Cash Flow and Debt Reduction Occidental reported a robust $2.6 billion in operating cash flow for Q2 2025, even amid lower oil prices. The company achieved a remarkable debt reduction, repaying $7.5 billion within a year, which represents nearly a 70% reduction of the debt incurred for the CrownRock acquisition. This financial maneuvering underscores Occidental's commitment to strengthening its balance sheet. Operational Efficiency and Cost Savings The company highlighted significant operational efficiencies, achieving $150 million in expected operating cost savings in its U.S. onshore operations. This resulted in a reduction of per barrel costs to $8.55. International operations also contributed to cost savings, with an estimated $50 million reduction in operating expenses. Permian Basin and Well Performance Occidental reported improved drilling times in the Delaware Basin, achieving a 20% reduction, which lowered well costs below the 2025 target. Additionally, year-to-date Permian unconventional well costs saw a 13% decrease compared to 2024, reflecting the company's focus on cost-effective production. Midstream and Marketing Segment Success The midstream and marketing segment exceeded expectations, generating positive earnings due to improved crude marketing margins and higher sulfur pricing. This performance highlights the segment's ability to adapt and thrive in a challenging market environment. Advancements in Low Carbon Ventures Occidental made significant strides in its low carbon ventures, with the STRATOS project reaching a milestone as Trains 1 & 2 moved to operations. The company also signed new commercial agreements for carbon dioxide removal cells, reinforcing its commitment to environmental sustainability. Lower Oil Prices Impact The company faced a challenging environment with much lower oil prices in the first half of 2025. The average WTI price was $11 per barrel lower compared to the first half of 2024, impacting revenue streams. OxyChem Segment Challenges OxyChem faced difficulties with pre-tax income falling below guidance due to weaker-than-expected pricing for caustic and PVC. An oversupply in the market further pressured margins, presenting challenges for the segment. Gulf of America Production Constraints Production in the Gulf of America was constrained primarily due to third-party issues. As a result, Occidental reduced its offshore production guidance for the second half of the year, citing ongoing effects from these curtailments. Forward-Looking Guidance Looking ahead, Occidental provided guidance that emphasizes continued operational efficiency and financial discipline. The company reported operating cash flow of $2.6 billion for the second quarter and total production of 1.4 million BOE per day, surpassing production guidance. Debt reduction remains a priority, with $7.5 billion repaid following the CrownRock acquisition. The company also lowered capital guidance by $100 million, benefiting from improved drilling efficiencies in the Delaware Basin. Advancements in the STRATOS project and new carbon management agreements further highlight Occidental's forward-looking strategy. In conclusion, Occidental Petroleum Corp.'s earnings call reflected a company poised for growth, despite external pressures. The focus on debt reduction, operational efficiencies, and low carbon initiatives positions Occidental well for future success. Investors and market watchers will be keen to see how these strategies unfold in the coming quarters.
